 |
| |
| Apr-23-18 | Reiterated |
Citigroup |
Neutral |
$146 → $134 |
|
| Apr-18-18 | Reiterated |
Stifel |
Hold |
$145 → $135 |
|
| Jan-24-18 | Reiterated |
Stifel |
Hold |
$142 → $145 |
|
| Jan-12-18 | Reiterated |
Wells Fargo |
Outperform |
$155 → $160 |
|
| Jan-02-18 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Oct-18-17 | Reiterated |
Stifel |
Hold |
$140 → $142 |
|
| Oct-18-17 | Reiterated |
RBC Capital Mkts |
Outperform |
$144 → $147 |
|
| Oct-18-17 | Reiterated |
Leerink Partners |
Outperform |
$150 → $165 |
|
| Oct-16-17 | Reiterated |
Jefferies |
Buy |
$157 → $160 |
|
| Oct-11-17 | Upgrade |
Jefferies |
Hold → Buy |
|
|
| Oct-09-17 | Upgrade |
Wells Fargo |
Market Perform → Outperform |
|
|
| Sep-25-17 | Initiated |
Citigroup |
Neutral |
$140 |
|
| Sep-20-17 | Downgrade |
Goldman |
Neutral → Sell |
$125 → $130 |
|
| Jul-21-17 | Downgrade |
BTIG Research |
Neutral → Sell |
$110 |
|
| Jul-21-17 | Downgrade |
Alembic Global Advisors |
Neutral → Underweight |
|
|
| Jul-20-17 | Resumed |
Credit Suisse |
Outperform |
$148 |
|
| Jul-05-17 | Reiterated |
Morgan Stanley |
Overweight |
$135 → $140 |
|
| May-18-17 | Reiterated |
Stifel |
Hold |
$124 → $128 |
|
| May-15-17 | Upgrade |
JP Morgan |
Neutral → Overweight |
|
|
| Jan-26-17 | Downgrade |
Wells Fargo |
Outperform → Market Perform |
|
|
|
|
| Jun-22-18 04:15PM | J&J's Drug Unit Chief Expands Portfolio in Executive Shakeup Bloomberg |
| 03:29PM | [$$] Johnson & Johnson Remakes Top Leadership The Wall Street Journal |
| 12:31PM | Johnson & Johnson Appoints Senior Leaders to Executive Committee PR Newswire |
| 12:30PM | Johnson & Johnson Announces Retirement of Group Worldwide Chairman, Sandra E. Peterson PR Newswire |
| Jun-21-18 04:04PM | Crowning Achievement: Six Dividend Kings With 50+ Years of Rising Dividends TheStreet.com |
| 12:27PM | This one factor has determined which stocks rise or fall on trade-war fears MarketWatch |
| Jun-20-18 06:01AM | Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks Motley Fool |
| 06:00AM | Heres how much Houston public companies spent on litigation in 2017 American City Business Journals |
| Jun-19-18 03:09PM | The Charts and Indicators on Johnson & Johnson Are Still Mostly Bearish TheStreet.com |
| 02:07PM | Opioid Ruling Could Send Purdue, Drugmakers to Court Bloomberg |
| 10:04AM | Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results PR Newswire |
| 07:10AM | 3 Stocks That Are Absurdly Cheap Right Now Motley Fool |
| 04:45AM | FOCUS-After split from Actelion, Idorsia CEO plans to raise more cash in 2019 Reuters |
| Jun-18-18 06:42PM | Cramer floats idea for 'gloomy' ETF with Wall Street's mo... CNBC Videos |
| 06:30PM | Cramer floats idea for 'gloomy' ETF CNBC Videos |
| 04:18PM | Markets Right Now: Stocks look to recover from early skid Associated Press |
| 04:04PM | 3 Great Stocks for Retirees to Own TheStreet.com |
| 10:13AM | After split from Actelion, Idorsia CEO plans to raise more cash in 2019 Reuters |
| 09:19AM | FOCUS-After split from Actelion, Idorsia CEO plans to raise more cash in 2019 Reuters |
| 08:42AM | Why Geron Corporation Stock Is Heading Higher Today Motley Fool |
| 08:27AM | FDA Approves the Next Generation of Customized LASIK Treatment with iDESIGN Refractive Studio PR Newswire |
| 07:27AM | UNF, Mayo experiment with rare 3-D microscope American City Business Journals |
| Jun-17-18 12:03PM | Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming Motley Fool |
| 10:06AM | Better Buy: Johnson & Johnson vs. Eli Lilly Motley Fool |
| 06:31AM | Better Buy: Pfizer Inc. vs. Johnson & Johnson Motley Fool |
| Jun-16-18 11:54PM | [$$] Global pharma bleeds talent to China start-ups Financial Times |
| Jun-15-18 05:01PM | LifeScan Global Corporation -- Moody's downgrades LifeScan Global's term loan B rating to B2 from B1 Moody's |
| 01:49PM | [$$] Can Investment Performance Be Predicted? Barrons.com |
| 11:52AM | 7 Perfect Dividend Stocks InvestorPlace |
| 10:55AM | Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III Zacks |
| 10:50AM | 10 Best Stocks to Buy and Hold Forever InvestorPlace |
| 09:25AM | Dow 30 Stock Roundup: Caterpillar Raises Dividend, Merck's Keytruda Gets FDA Nod Zacks |
| 09:04AM | Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health Zacks |
| 07:25AM | Estimating The Fair Value Of Johnson & Johnson (NYSE:JNJ) Simply Wall St. |
| Jun-14-18 08:30PM | Kyros Law is Investigating Claims on Behalf of Invokana users: 1,100 Invokana Lawsuits Alleging Diabetic Ketoacidosis, Kidney Injury, Amputations and Heart Complications Filed. PR Newswire |
| 05:38PM | Growth & Income Buys | Johnson & Johnson and International Paper Zacks |
| 01:41PM | 5 AI Biotech Stocks to Bet On Now InvestorPlace |
| 08:00AM | Factors of Influence in 2018, Key Indicators and Opportunity within Southwestern Energy, Johnson & Johnson, Sleep Number, QUALCOMM, Kirkland's, and Grupo Aval Acciones y Valores S.A New Research Emphasizes Economic Growth GlobeNewswire |
| Jun-13-18 04:34PM | Time Warner, Twenty-First Century Fox rise; H&R Block sinks Associated Press |
| 04:27PM | Deals of the day-Mergers and acquisitions Reuters |
| 10:41AM | J&J (JNJ) Accepts Platinum Equity's Offer for LifeScan Unit Zacks |
| Jun-12-18 08:12PM | [$$] Ever Heard of Iqvia? Its CEO Made $38 Million The Wall Street Journal |
| 05:25PM | AI And Robotics Are Taking Robotic Surgery To New Levels Investor's Business Daily |
| 05:13PM | [$$] Iqvia? Its CEO Was the Highest Paid Pharma Chief The Wall Street Journal |
| 05:02PM | [$$] Johnson & Johnson Accepts Platinum Equity's $2.1 Billion Offer for LifeScan Business The Wall Street Journal |
| 04:31PM | J&J Formally Accepts $2.1 Billion Offer for Diabetes Device Unit Bloomberg |
| 04:30PM | J&J accepts $2.1 billion bid for its LifeScan diabetes business CNBC |
| 04:26PM | J&J accepts $2.1 billion offer for its LifeScan unit Reuters |
| 04:18PM | Why Dow's J&J May Try To Sweep Boston Scientific From Stryker Investor's Business Daily |
| 04:12PM | Johnson & Johnson accepts $2.1B deal for LifeScan business MarketWatch |
| 04:12PM | J&J accepts $2.1 bln offer for its LifeScan unit Reuters |
| 04:01PM | Johnson & Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc. PR Newswire |
| 10:24AM | Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate Zacks |
| 10:04AM | Amgen Gets FDA Nod to Add ASPIRE Data on Kyprolis Label Zacks |
| 09:25AM | Alzheimer's Research Stumbles Again: What's the Road Ahead? Zacks |
| 08:30AM | Stryker Likely to Acquire Boston Scientific, Shares Down Zacks |
| 07:58AM | Pharma R&D Investments Moderating -- But Still High Forbes |
| 12:40AM | [$$] AstraZeneca and Eli Lilly scrap Alzheimers drug trial Financial Times |
| Jun-11-18 04:16PM | Better Buy: Verizon Communications Inc. vs. Johnson & Johnson Motley Fool |
| 02:21PM | Investors ready to resuscitate Johnson & Johnson's ailing stock Reuters |
| Jun-09-18 10:15AM | 3 Top Dividend Stocks to Buy in June Motley Fool |
| Jun-08-18 04:22PM | Bourdain, Spade suicides highlight need for new depression drugs Reuters |
| 02:41PM | J&J Exec Makes First Microsoft Insider Stock Buy Since 2015 Barrons.com |
| 10:53AM | Dying Patients Seeking Drugs Face Reality Check on Right to Try Bloomberg |
| 09:21AM | 3 Dividend Stocks Perfect for Retirees Motley Fool |
| 08:18AM | Better Buy: GlaxoSmithKline plc vs. Johnson & Johnson Motley Fool |
| Jun-07-18 10:43PM | Asian shares fall ahead of G7 summit, central bank meetings Associated Press |
| 06:50PM | Cramer: Don't be afraid to pay up for best-of-breed stock... CNBC Videos |
| 04:37PM | Fortive offers $2.7 billion to buy Johnson & Johnson's medical-equipment sterilization business American City Business Journals |
| 01:19PM | Allergan on an upswing, Vail Resorts soars, Johnson & Johnson dips Yahoo Finance |
| 11:08AM | Allergan, Vail Resorts and Johnson & Johnson are the Yahoo Finance charts of the day. Yahoo Finance Video |
| 10:39AM | China will see the biggest boost in World Cup ad dollars even though it didnt qualify CNBC |
| 10:11AM | J&J Receives Buyout Offer for Sterilization Products Unit Zacks |
| 09:24AM | Stocks to Watch: Boeing, Tesla, Allergan, Amazon, Alibaba, Smucker The Wall Street Journal |
| 08:14AM | Stocks making the biggest moves premarket: SJM, THO, FIVE, UNFI, ZS, AGN, JNJ, TRUE & more CNBC |
| 07:58AM | Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study Benzinga |
| Jun-06-18 08:49PM | [$$] Fortive Offers $2.7 Billion for J&J's Medical-Equipment Sterilization Business The Wall Street Journal |
| 06:34PM | J&J gets $2.7 billion offer for sterilization unit from Fortive Reuters |
| 06:31PM | J&J gets $2.7 bln offer for sterilization unit from Fortive Reuters |
| 05:21PM | In Missouri, J&J faces biggest trial yet alleging talc caused cancer Reuters |
| 05:12PM | J&J to sell sterilization unit to Fortive for $2.7 billion Reuters |
| 05:04PM | Fortive to acquire Johnson & Johnson sterilization business for $2.7 billion MarketWatch |
| 04:48PM | Fortive offers $2.7 bln for J&J unit's sterilization business Reuters |
| 04:46PM | Johnson & Johnson Announces Binding Offer from Fortive Corporation to Acquire Advanced Sterilization Products (ASP) PR Newswire |
| 03:21PM | Corrections & Amplifications The Wall Street Journal |
| 11:53AM | Boston U. boosts lung cancer research with Johnson & Johnson Associated Press |
| 11:17AM | The Top 4 UPS Shareholders (UPS) Investopedia |
| 05:00AM | J&J Faces High-Stakes Trial Over 22 Women's Talc Claims Bloomberg |
| Jun-05-18 09:31PM | Is an Acquisition in Portola Pharmaceuticals' Future? Motley Fool |
| 05:26PM | Sanofi, Merck and J&J Tout Lower Drug Prices TheStreet.com |
| 08:00AM | Johnson & Johnson Announces Progress Toward Health for Humanity Goals PR Newswire |
| Jun-04-18 09:00AM | James Allison, Ph.D., Wins 2018 Dr. Paul Janssen Award for Biomedical Research PR Newswire |
| Jun-03-18 06:35PM | U.S. FDA wants to shorten new drug monopolies to cut costs Reuters |
| Jun-01-18 12:26PM | Imerys unit settles talc claims for at least $5 million: Bloomberg Reuters |
| 10:25AM | Imerys Unit Said to Settle Talc Claims for at Least $5 Million Bloomberg |
| 07:30AM | Breakfast Technical Briefing on Johnson & Johnson and Three Other Additional Healthcare Stocks ACCESSWIRE |
| May-31-18 11:30PM | [$$] Big Pharma on mission to bring immunotherapy to more patients Financial Times |
| 10:58AM | Top Diabetes Stocks to Buy Today Motley Fool |
| May-30-18 03:39PM | 7 Inflation-Beating Stocks to Consider for This New Reality InvestorPlace |
| 08:10AM | Add Bucks County to list of those suing opioid manufacturers, distributors American City Business Journals |
|
|
|
|
| Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The company's Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension diseases. Its Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 15 | Option Exercise | 90.44 | 155,342 | 14,049,130 | 357,906 | Feb 20 07:46 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 15 | Sale | 129.86 | 155,342 | 20,172,401 | 202,564 | Feb 20 07:46 PM | | Caruso Dominic J | Exec VP, Finance; CFO | Feb 09 | Option Exercise | 0.00 | 10,601 | 0 | 154,703 | Feb 13 06:54 PM | | Duato Joaquin | Exec VP, WW Chair, Pharma | Feb 09 | Option Exercise | 0.00 | 9,812 | 0 | 78,348 | Feb 13 06:54 PM | | Fasolo Peter | Exec VP, Chief HR Officer | Feb 09 | Option Exercise | 0.00 | 5,830 | 0 | 69,992 | Feb 13 06:54 PM | | Gorsky Alex | Chairman, CEO | Feb 09 | Option Exercise | 0.00 | 33,165 | 0 | 285,990 | Feb 13 06:54 PM | | PETERSON SANDRA E | Exec VP, Group WW Chairman | Feb 09 | Option Exercise | 0.00 | 11,445 | 0 | 70,205 | Feb 13 06:54 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 09 | Option Exercise | 0.00 | 13,252 | 0 | 181,655 | Feb 13 06:55 PM | | Ullmann Michael H | Exec VP, General Counsel | Feb 09 | Option Exercise | 0.00 | 5,953 | 0 | 115,257 | Feb 13 06:55 PM | | Kapusta Ronald A | Controller, CAO | Feb 09 | Option Exercise | 0.00 | 2,702 | 0 | 32,666 | Feb 13 06:55 PM | | Mesquita Jorge S. | Exec VP, WW Chair, Consumer | Feb 02 | Option Exercise | 0.00 | 32,688 | 0 | 32,688 | Feb 06 04:21 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Oct 31 | Option Exercise | 0.00 | 75,492 | 0 | 203,142 | Nov 02 05:01 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Jul 24 | Option Exercise | 72.54 | 102,692 | 7,449,278 | 230,342 | Jul 26 11:49 AM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Jul 24 | Sale | 133.14 | 102,692 | 13,672,629 | 127,650 | Jul 26 11:49 AM | | Caruso Dominic J | Exec VP, Finance; CFO | Jul 20 | Option Exercise | 61.75 | 82,591 | 5,099,994 | 226,693 | Jul 24 11:06 AM | | Caruso Dominic J | Exec VP, Finance; CFO | Jul 20 | Sale | 136.72 | 82,591 | 11,291,478 | 144,102 | Jul 24 11:06 AM |
|
|
|
|
|
|
